Hints and tips:
Related Special Reports
...Other investors in the company are Sanofi Ventures and the Cambridge university’s venture fund....
...The company reiterated that it expected earnings per share to decline by a “low single-digit” percentage this year before rebounding in 2025, as it gears up to spend more on internal research and development...
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...Dani Saurymper, an asset manager for Pacific Asset Management and small GSK shareholder, said Sanofi’s decision and recent settlements by GSK showed that companies would “rather settle any liability than...
...The company spent €6.7bn on R&D last year. It plans to spend an additional €700mn next year. That is not eye-popping. Sanofi’s R&D spend last year was 15.6 per cent of revenues....
...Sanofi chief executive Paul Hudson has admitted he could have done a better job explaining aspects of a multibillion-euro investment plan to shareholders, ahead of a meeting where he will try to sell them...
...French pharmaceuticals company Sanofi is exploring options to spin out and list its consumer care division as an independent company as early as the end of next year, most likely through a listing in Paris...
...Sanofi has since restructured its consumer division as a standalone business within the company....
...Sanofi has since restructured the consumer division to be a standalone business within the company....
...Germany’s Bayer and French giant Sanofi, which makes polio vaccines, have followed suit....
...For some pharma groups, notably Sanofi of France, the pandemic was a time of embarrassing and very public underperformance....
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...UK’s AstraZeneca, German software company SAP and French healthcare firm Sanofi....
...But on Tuesday night, the company announced it had failed to reduce relapse rates for MS patients compared with teriflunomide, which is produced by rival Sanofi....
...The company has warned of zero free cash flow for 2023....
...AstraZeneca is buying its first vaccine company in a deal worth up to $1.1bn, as it invests in the infectious disease unit it set up during the Covid-19 pandemic....
...Earnings: Oil major Shell, beverage maker AG Barr and air carrier Icelandair will report, as will casino operator Rank Group and biopharma companies Novozymes, Roche and Sanofi....
...company....
...Oxford-based Exscientia is working with Sanofi and Bristol Myers Squibb, among others, and Insitro has a deal with Bristol Myers, while Owkin is also collaborating with Sanofi....
...Big share price moves in Europe today include French drug company Sanofi, French video game maker Ubisoft and Dutch lighting company Signify: Sanofi: Shares in the French drugmaker dropped more than 15...
...The Darmstadt-based company said on Tuesday night that its drug called evobrutinib had failed to reduce relapse rates for patients compared to teriflunomide — an ingredient in rival drugmaker Sanofi’s Aubagio...
...After last year’s slump, biotech M&A has surged this year. The companies best placed to replenish Big Pharma’s pipeline have attracted premium prices....
...Novartis trades on a forward price/earnings ratio of 13.6, higher than some European peers such as Roche and Sanofi....
...AstraZeneca already has expertise in RSV, as the drugmaker sells an antibody that protects infants from the disease in partnership with Sanofi. It also markets a nasal flu vaccine....
International Edition